Clinical Trials
50 trialsIs Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?
Tianjin Medical University Second Hospital
eRapa
The University of Texas Health Science Center at San Antonio
GAIN-BCG
Alliance for Clinical Trials in Oncology
Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging
Oslo University Hospital
CISTO
University of Washington
A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)
Memorial Sloan Kettering Cancer Center
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Memorial Sloan Kettering Cancer Center
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
Roswell Park Cancer Institute
TVNIM-AFU
Association Francaise d'Urologie
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
CISTO2
University of Washington
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
ADAPT-BLADDER
Hoosier Cancer Research Network
Tumor Budding and T1 Substaging in Urothelial Bladder Cancer
Assiut University
BladMetrix
Oslo University Hospital
ENHANCE
Hoosier Cancer Research Network
Study of CG0070 After Transurethral Resection in Patients With IR NMIBC
H. Lee Moffitt Cancer Center and Research Institute
VG-INFUSE Tria
Fudan University
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Mayo Clinic
MiLUT
University of Zurich
PRO-GAG
BLAD-HYA Group
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
Ohio State University Comprehensive Cancer Center
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
University of California, Davis
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
Tianjin Medical University Second Hospital
CRUCIAL-R
S. Andrea Hospital
Hydeal Cyst
Istituto Oncologico Veneto IRCCS
Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)
Mayo Clinic
En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer
Aarhus University Hospital
SPICE
University of Aarhus
PERTINENCE
Institut Cancerologie de l'Ouest
CUT-less
University of Roma La Sapienza
BicaBCa
CHU de Quebec-Universite Laval
TRAIN
The Christie NHS Foundation Trust
PERSEVERANCE
Institut Cancerologie de l'Ouest
NMIBC
Xijing Hospital
ALU
Hopital Foch
Mood Alterations in the Patients With Non-Muscle Invasive Bladder Cancer Treated With BCG
Johns Hopkins University
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HERO
Fudan University
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
COBRA-NMIBC
Aarhus University Hospital
GEM-IR-NMIBC
Shanghai University of Traditional Chinese Medicine
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Lahey Clinic
A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy
Ractigen Therapeutics.
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)
University of Texas Southwestern Medical Center
RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients
Peking University First Hospital
BCG-TIME
Queen's University
Observational Clinical Study on High - Risk NMIBC Patients Choosing Trimodality Bladder - Sparing Therapy
Peking University First Hospital
A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing
The First Affiliated Hospital with Nanjing Medical University